Our study, for the first time, shows that treating mice that contain breast cancer brain metastatic macrometastasis with an ACSS2 inhibitor is effective in shrinking tumors in the brain parenchyma and also can extend survival of these mice. Here, ACSS2 is linked to breast cancer.